Biotech Values

[DewDiligence]

LOGC IPOs 8.05M* shares @$10.00:

https://www.prnewswire.com/news-releases/arix-bioscience-plc-logicbio-prices-nasdaq-ipo-852201300.html

LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using GeneRide, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene, in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. Headquartered in Cambridge, Massachusetts, LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

*Assuming exercise of underwriter’s option.